Project CBD

MAY 3, 2023

Dr. Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children.

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

Medical Marijuana Program Connection

JANUARY 31, 2023

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Market Size, Forecast, Insights, and Competitive Landscape” report has been added to ResearchAndMarkets.com’s offering. Read More

Clinical Trials 52

Clinical Trials Business Cannabis 52

Medical Marijuana Program Connection

JANUARY 4, 2024

I’m always skeptical of claims concerning therapeutic uses of CBD oil (cannabidiol) and also the results of clinical trials that contain a small number of participants. Read More

Oil 49

Oil Clinical Trials CBD 49

Cannabis Law Report

MAY 26, 2023

Gardiner, Rocky Swanson May 24, 2023 After a period of intense market interest in 2021, investment in psychedelics has cooled somewhat, although results from clinical trials remain positive. Here’s the introduction to the piece By Kimberly Burns, Rose M. Carter, Karen M. Lexpert spoke with Kimberly Burns, Rose M.

Clinical Trials 52

Clinical Trials 52

Cannabis Law Report

JANUARY 25, 2023

Vancouver, British Columbia, January 18, 2023 – Filament Health Corp.

Clinical Trials 52

Clinical Trials Treatment 52

Veriheal

MARCH 2, 2024

In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.

Legalization 110

Legalization Epilepsy Clinical Trials THC 110

Medical Marijuana Program Connection

FEBRUARY 27, 2023

The cannabis oil will be used as a part of the Company‘s proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL. Read More

Clinical Trials 52

Clinical Trials Oil CBD Treatment 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

SEPTEMBER 23, 2022

MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since MAPS was founded, philanthropic donors and grantors have given more than $130 million for psychedelic and marijuana research and education.

Decriminalization 52

Decriminalization Advocacy Research and Development Clinical Trials 52

Cannabis Law Report

APRIL 27, 2022

MDMA-assisted therapy has already shown incredible results in the stage three clinical trials for individuals suffering from severe PTSD,” Ginal told committee members. “I Patrick Neville (R) and David Ortiz (D), along with Sens. John Cooke (R) and Joann Ginal (D). I ask for your support on this bill.”.

Clinical Trials 52

Clinical Trials Legalization Therapy Food 52

Cannabis Law Report

OCTOBER 2, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

MAY 12, 2022

Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora expects LPH-5 to be IND ready in Q4 2022 and plans to begin first-in-human trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

The Joint Blog

JANUARY 12, 2020

billion by 2023, according to the cannabis research firm Brightfield Group and noted by the AP. A small clinical trial at Colorado State University published in the Journal of the American Veterinary Medical Association in June found CBD oil reduced seizure frequency in 89 percent of the epileptic dogs that received it.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Cannabis Law Report

FEBRUARY 9, 2022

“They have a couple of pieces that they need to report back on in relation to safety, social impact, review of any new or ongoing clinical trials,” Backstrom said. Oregon’s new psilocybin system is scheduled to begin in January 2023. Just to be sure that … they are still safe and applicable.”. Source: [link].

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States.

Law 52

Law Programs Therapy Education 52

Project CBD

FEBRUARY 27, 2023

Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. Trials vol. 2023, doi:10.1186/s13063-023-07078-6 Kurlyandchik, Inna et al.

THC 144

THC CBD Clinical Trials Sleep 144

Cannabis Law Report

DECEMBER 21, 2021

billion in 2023. Payal Keswarpu, presented cerVIA™ clinical study results at the 17th World Congress for Cervical Pathology and Colposcopy before 42 participating countries. The second phase of cerVIA™ clinical trials in India is complete, with white paper submissions underway. billion (2020).

Research and Development 40

Research and Development Supply Chain Data Business 40

Project CBD

MARCH 21, 2023

Auditory & Other Symptoms The survey, whose findings were published in February 2023 in the Journal of Otolaryngology – Head & Neck Surgery 1 evaluated cannabis perceptions and consumption among 45 adult tinnitus patients randomly selected and recruited from an outpatient ear, nose, and throat clinic in Ontario, Canada.

Cannabinoids 144

Cannabinoids Clinical Trials Sleep Blood Pressure 144

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. Berra Yazar-Klosinski, Ph.D.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

FEBRUARY 14, 2023

CAMH will study PEX010, Filament’s botanical psilocybin drug candidate, in a Health Canada-approved clinical trial for mild cognitive impairment VANCOUVER, BC, Feb. 14, 2023 /CNW/ – Filament Health Corp.

Clinical Trials 52

Clinical Trials 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”).

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

AUGUST 18, 2022

It is anticipated that MDMA will receive FDA approval for PTSD by the end of 2023, and that psilocybin approval will follow. Federally, the FDA also has granted “breakthrough therapy designation” for MDMA and psilocybin to expedite development and agency review.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

DECEMBER 21, 2021

Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. The company, which began trading on the OTC and Frankfurt Stock exchanges in October, has plans to open as many as 120 more clinics by 2023.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MAY 29, 2022

As previously mentioned, clinical studies are promising, including a Phase 3 trial (the last step before submitting an NDA) completed last November. [9] 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] Clinical Trials and Human Subject Protections. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JULY 29, 2022

The duo filed separate amendments on expanding psychedelics research to service members that earlier this month got attached to the fiscal 2023 National Defense Authorization Act ( H.R. The trials would study treatments with psilocybin, MDMA, and ibogaine — a naturally occurring psychoactive substance — Crenshaw said.

Clinical Trials 52

Clinical Trials Treatment Legislation Programs 52

The Blunt Truth

FEBRUARY 17, 2023

I am honored to have Congressman Bergman, Senate Committee on Veterans’ Affairs Chairman Jon Tester, and Senator Dan Sullivan join me in taking action to help veterans in need of medical cannabis and opioid alternatives.

Clinical Trials 96

Clinical Trials Banking Chronic Pain Media 96

Veriheal

NOVEMBER 7, 2024

Not only would medicinal cannabis-derived products become more legally available for patients’ use, but a successful rescheduling would also open increased opportunities for new clinical trials, helping to further the advancement of therapeutic options available. drug policy and public opinion regarding cannabis’ status as a medicine.

DEA 97

DEA Policy Chronic Pain Marijuana 97

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. California. The new law went into immediate effect upon the governor’s signature on October 12, 2019. The law will take effect on January 1, 2020.

Legislation 45

Legislation Patients Access Banking 45